Photophobia and migraine outcome during treatment with galcanezumab.

Schiano di Cola, Francesca; Ceccardi, Giulia; Bolchini, Marco; Caratozzolo, Salvatore; Liberini, Paolo; Padovani, Alessandro; Rao, Renata

Schiano di Cola, Francesca; Ceccardi, Giulia; Bolchini, Marco; Caratozzolo, Salvatore; Liberini, Paolo; Padovani, Alessandro; Rao, Renata.

Afiliación

Schiano di Cola F; Neurology Unit, Department of Clinical and Experimental Sciences, ASST Spedali Civili, University of Brescia, Brescia, Italy.
Ceccardi G; Neurology Unit, Department of Clinical and Experimental Sciences, ASST Spedali Civili, University of Brescia, Brescia, Italy.
Bolchini M; Neurology Unit, Department of Clinical and Experimental Sciences, ASST Spedali Civili, University of Brescia, Brescia, Italy.
Caratozzolo S; Neurology Unit, Department of Clinical and Experimental Sciences, ASST Spedali Civili, University of Brescia, Brescia, Italy.
Liberini P; Neurology Unit, Department of Clinical and Experimental Sciences, ASST Spedali Civili, University of Brescia, Brescia, Italy.
Padovani A; Neurology Unit, Department of Clinical and Experimental Sciences, ASST Spedali Civili, University of Brescia, Brescia, Italy.
Rao R; Neurology Unit, Department of Clinical and Experimental Sciences, ASST Spedali Civili, University of Brescia, Brescia, Italy.

Front Neurol ; 13: 1088036, 2022.

Article en En | MEDLINE | ID: mdl-36742057

Palabras clave

CGRP; disability; galcanezumab; light; migraine; photophobia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Observational_studies Idioma: En Revista: Front Neurol Año: 2022 Tipo del documento: Article País de afiliación: Italia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google